- Home
- Publications
- Publication Search
- Publication Details
Title
Myelofibrosis, JAK2 inhibitors and erythropoiesis
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 6, Pages 1219-1223
Publisher
Springer Nature
Online
2013-06-05
DOI
10.1038/leu.2013.72
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1
- (2013) I. Ambaglio et al. HAEMATOLOGICA
- Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera
- (2012) A. Mullally et al. BLOOD
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
- (2012) A. L. Godfrey et al. BLOOD
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia
- (2012) Stefano Rivella BLOOD REVIEWS
- Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap
- (2012) Camelia Iancu-Rubin et al. EXPERIMENTAL HEMATOLOGY
- Emerging drugs for myelofibrosis
- (2012) Ehab Atallah et al. EXPERT OPINION ON EMERGING DRUGS
- Targeting JAK2 in the therapy of myeloproliferative neoplasms
- (2012) Mamatha M Reddy et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms
- (2012) Anna L. Godfrey et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
- (2012) Oliver Weigert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- RBC-transfusion guidelines update
- (2012) R.P. Gale et al. LEUKEMIA RESEARCH
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
- (2012) Adam J. Mead et al. NEW ENGLAND JOURNAL OF MEDICINE
- Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
- (2012) Ayalew Tefferi NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis
- (2011) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
- (2011) M. M. Patnaik et al. BLOOD
- -thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism
- (2011) Y. Ginzburg et al. BLOOD
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis
- (2011) Cyril Quivoron et al. CANCER CELL
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
- (2011) Kelly Moran-Crusio et al. CANCER CELL
- Mouse models of myeloproliferative neoplasms: JAK of all grades
- (2011) J. Li et al. Disease Models & Mechanisms
- Orientation-specific signalling by thrombopoietin receptor dimers
- (2011) Judith Staerk et al. EMBO JOURNAL
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
- (2011) T L Lasho et al. LEUKEMIA
- Dnmt3a is essential for hematopoietic stem cell differentiation
- (2011) Grant A Challen et al. NATURE GENETICS
- JAK2 impairs stem cell function?
- (2010) R. C. Skoda BLOOD
- JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
- (2010) J. Li et al. BLOOD
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
- (2008) C. James et al. BLOOD
- JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
- (2008) William Vainchenker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now